Trial reportMedicine2016
Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial.
Trial report in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Effect of cabergoline on the management of diabetes mellitus: a systematic review and meta-analysis.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Prediabetes May Alter HPA Axis Activity and Regulation: A Study on Patients with Prediabetes.International journal of molecular sciences · 2025Article
- Bromocriptine in type 2 diabetes: a promising alternative, a systematic review and meta-analysis.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Dopamine Agonists as a Novel "Cure" for Autoimmune Diabetes.JCEM case reports · 2024Article
- Genotype-negative multiple endocrine neoplasia type 1 with prolactinoma, hyperparathyroidism, and subclinical Cushing's syndrome accompanied by hyperglycemia: a case report.Frontiers in endocrinology · 2024Article
- Dopamine 2 agonists for the management of type 2 diabetes: a systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2023Review
- Article
- Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions.Frontiers in clinical diabetes and healthcare · 2023Review
- The interplay between prolactin and cardiovascular disease.Frontiers in endocrinology · 2022Review
- Metabolic effects of prolactin.Frontiers in endocrinology · 2022Review
- Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus.Journal of feline medicine and surgery · 2021Article
- Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.Frontiers in endocrinology · 2021Article
- The Interplay Between Pituitary Health and Diabetes Mellitus - The Need for 'Hypophyseo-Vigilance'.European endocrinology · 2020Review
- Dopamine DPsychoneuroendocrinology · 2020Article
- Dopaminergic Pathways in Obesity-Associated Inflammation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.Internal medicine (Tokyo, Japan) · 2019Article
- Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis.Endocrine connections · 2019Article
- Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas.Frontiers in endocrinology · 2019Review
- Diabetes Mellitus Secondary to Cushing's Disease.Frontiers in endocrinology · 2018Review
- Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.Reviews in endocrine & metabolic disorders · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCabergoline is a long-acting agonist of dopamine, which has a high affinity to dopamine receptors (type 2). Treatment using a dopaminergic agonist reduces hypothalamic stimulation that increases during liver gluconeogenesis, lipids synthesis, and insulin resistance. Our aim was to evaluate the effects of cabergoline on blood glucose levels in patients with type 2 diabetes mellitus (DM).
methodsThis study was a double-blind, controlled clinical trial in patients with type 2 DM. The patients received treatments of a placebo (control group; n = 20) or cabergoline 0.5 mg (cabergoline group; n = 20) using the sequential method, once per week for 3 months, while using previously prescribed glucose-lowering drugs. All tests, such as levels of fasting blood glucose, 2-hour post-prandial glucose, complete lipid profile, prolactin, alanine amino transferase, aspartate amino transferase, creatinine, blood urea nitrogen, and serum insulin, and homeostasis model assessment insulin resistance were measured at baseline and at 3-month follow-up.
resultsThe fasting blood sugar levels were significantly different between placebo and cabergoline groups after 3 months of treatment (P = 0.004). The prolactin levels were significantly different from beginning of the treatment to 6 months later (P = 0.001). In the cabergoline group, there was a significant decrease in glycosylated hemoglobin (HbA1C) levels after 3 months (P = 0.003). Overall, 65%and 45% patients in the cabergoline and control groups, respectively, responded to treatment (HbA1C<7%).
conclusionCabergoline may be useful as a long-acting antidiabetic agent in patients with type 2 diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.